Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.
Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.1
Select an option below to learn more about the efficacy, safety and mode of action, and to access dedicated resources to help you support your patients with AD.
Discover the benefits that Cibinqo can offer your patients with moderate-to-severe AD.
Learn more about JAK inhibition, the role of the JAK/STAT pathway and how Cibinqo works.
Cibinqo has been studied across six Phase III trials as monotherapy or in combination with medicated topical therapies.1–7
3,128 patients were treated with Cibinqo in clinical studies in AD representing 2,089 patient-years of exposure.1
Discover which patients may be suitable for treatment with Cibinqo.
Learn more about flexible dosing in patients on Cibinqo.
Access resources to help you support your patients on Cibinqo.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 200 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 100 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 50 mg film-coated tablets.
Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021